Based on the two aforementioned works (102, 103), it seems interesting to develop therapies with miRNAs aimed at reducing HLA-G expression in cancer, in order to restore the anti-tumor activity of cells restrained by this molecule. The gene discussed is HLA-G; the disease is cancer.